Quarterly ResultSep 28, 2026, 07:14 AM
Addex Therapeutics Reports Q2 2026 Net Loss of CHF 1.74M
AI Summary
Addex Therapeutics Ltd. has released its unaudited interim condensed consolidated financial statements for the periods ended June 30, 2026. The company reported a net loss of CHF 1.74 million for the three months ended June 30, 2026, and CHF 3.46 million for the six months ended June 30, 2026. Total assets, liabilities, and equity all saw significant decreases by the end of the second quarter of 2026 compared to the end of 2025. The company continues to face challenges in its development programs, with several partnerships terminated and a stated need for additional funding.
Key Highlights
- Addex Therapeutics Ltd. reported a net loss of CHF 1.74 million for the three months ended June 30, 2026, compared to a net loss of CHF 1.84 million for the same period in 2025.
- For the six months ended June 30, 2026, the net loss was CHF 3.46 million, compared to CHF 3.31 million for the same period in 2025.
- Total assets decreased to CHF 3.48 million as of June 30, 2026, from CHF 6.36 million as of December 31, 2025.
- Total liabilities decreased to CHF 1.57 million as of June 30, 2026, from CHF 1.60 million as of December 31, 2025.
- Total equity decreased to CHF 1.91 million as of June 30, 2026, from CHF 4.77 million as of December 31, 2025.
- Operating costs for the six months ended June 30, 2026, were CHF 1.14 million, a decrease from CHF 1.45 million in the prior year period.
- Research and development expenses for the six months ended June 30, 2026, were CHF 74,115, a decrease from CHF 390,520 in the prior year period.
Price Impact
More from ADXN